Omnicell (NASDAQ:OMCL) Downgraded by StockNews.com to “Hold”

StockNews.com lowered shares of Omnicell (NASDAQ:OMCL) from a buy rating to a hold rating in a research note issued to investors on Wednesday.

Other equities research analysts have also issued research reports about the company. Barclays upped their price objective on Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Wells Fargo & Company raised their price target on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research report on Monday, October 14th. JPMorgan Chase & Co. upped their price objective on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Benchmark restated a “buy” rating and set a $48.00 target price on shares of Omnicell in a research report on Wednesday, October 9th. Finally, Craig Hallum upped their price target on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $52.00.

Omnicell Trading Down 3.9 %

Shares of NASDAQ OMCL opened at $46.59 on Wednesday. The company has a 50 day simple moving average of $44.55 and a two-hundred day simple moving average of $37.99. The stock has a market cap of $2.16 billion, a price-to-earnings ratio of -119.46, a PEG ratio of 36.82 and a beta of 0.81. Omnicell has a 12 month low of $25.12 and a 12 month high of $55.74.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC lifted its stake in shares of Omnicell by 248.8% in the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after buying an additional 1,000 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after buying an additional 553 shares in the last quarter. CWM LLC lifted its stake in shares of Omnicell by 68.2% in the second quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after buying an additional 1,236 shares in the last quarter. 1620 Investment Advisors Inc. lifted its stake in shares of Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after buying an additional 1,542 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new position in shares of Omnicell in the second quarter worth about $104,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.